The ABATE trial is studying the effects of a study vaccine named ACI-24.060 in people with early Alzheimer’s disease. A build-up of protein Abeta (Aβ) in the brain is believed to play an important role in cognitive decline in Alzheimer’s disease. ACI-24.060 is designed to help reduce the quantity of ... Read More
Part II of the ABATE Study explores the effect of a new vaccine called ACI-24.060 on people with Down’s syndrome. People with Down’s syndrome have an increased risk of developing Alzheimer’s Disease. Alzheimer’s disease is caused by an increased level of ABeta (Aβ) protein leading to slowing down ... Read More
This trial is testing an investigational medication in people who have early Alzheimer’s disease. Researchers want to learn about the safety of the investigational medication and how well it may work to slow the progression of Alzheimer’s disease. ... Read More
